Innovations in Oncology- Focus on Acute Myeloid Leukemia

Course Description:

The treatment landscape for patients diagnosed with acute myeloid leukemia (AML) has undergone significant growth over the last five years with numerous practice-changing FDA approvals. These, predominantly oral, agents introduce new toxicity profiles, drug interactions, and financial implications to the AML treatment paradigm.  Patient-centered targeted treatment design incorporating molecular aberrations, pharmacoeconomic considerations, and novel pathways is now considered the standard of care.  Additional promising therapies are currently in the pipeline with a variety of new pathways and treatment approaches under investigation. During this session, presenters will discuss new data, recent changes to treatment guidelines, and explore emerging innovations and controversies that may impact acute myeloid leukemia management in the future. Novel therapies in development and evolving targets will be discussed, including potential roles in treatment.

Learning Objectives:

At the completion of this knowledge-based activity, participants should be able to

  1. Describe the current treatment landscape for acute myeloid leukemia according to subtype.
  2. Recognize the mechanisms of action for promising emerging treatment options for patients with acute myeloid leukemia.
  3. Explain the potential impact of emerging treatment options on acute myeloid leukemia treatment guidelines and recommendations.


Kayleigh R. Marx, PharmD, BCOP

Leukemia Clinical Pharmacy Specialist

University of Texas MD Anderson Cancer Center

Houston, TX


Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth


Coconut Creek, FL

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN: 0233-9999-21-038-H01-P  • Activity Type: Knowledge-Based
Contact Hours: 0.5
Release Date: November 4, 2021 •  Expiration Date: December 31, 2022
Activity Fee: Free for Members and Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented upon release. Virtual.CPE credit will be processed and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

Commercial Support:

This educational activity is supported by unrestricted educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-9999-21-038-H01-P 0.5 Contact Hours November 04, 2021 - December 31, 2022